Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells

Martine Cordeau; Assila Belounis; Martin Lelaidier; Paulo Cordeiro; Hervé Sartelet; Sabine Herblot; Michel Duval

doi:10.1371/journal.pone.0164401

Abstract

High-risk neuroblastoma (NB) remains a major therapeutic challenge despite the recent advent of disialoganglioside (GD2)-antibody treatment combined with interleukin (IL)-2 and granulocyte monocyte-colony stimulating factor (GM-CSF). Indeed, more than one third of the patients still die from this disease. Here, we developed a novel approach to improve the current anti-GD2 immunotherapy based on NK cell stimulation using toll-like receptor (TLR)-activated plasmacytoid dendritic cells (pDCs). We demonstrated that this strategy led to the efficient killing of NB cells. When the expression of GD2 was heterogeneous on NB cells, the combination of pDC-mediated NK-cell activation and anti-GD2 treatment significantly increased the cytotoxicity of NK cells against NB cells. Activation by pDCs led to a unique NK-cell phenotype characterized by increased surface expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with increased expression of CD69 on CD56^dim cytotoxic cells, and strong interferon-γ production. Additionally, NB-cell killing was mediated by the TRAIL death-receptor pathway, as well as by the release of cytolytic granules via the DNAX accessory molecule 1 pathway. NK-cell activation and lytic activity against NB was independent of cell contact, depended upon type I IFN produced by TLR-9-activated pDCs, but was not reproduced by IFN-α stimulation alone. Collectively, these results highlighted the therapeutic potential of activated pDCs for patients with high-risk NB.

Citation: Cordeau M, Belounis A, Lelaidier M, Cordeiro P, Sartelet H, Herblot S, et al. (2016) Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells. PLoS ONE 11(10): e0164401. https://doi.org/10.1371/journal.pone.0164401

Editor: Antonio Perez-Martinez, Hospital Infantil Universitario Nino Jesus, SPAIN

Received: June 7, 2016; Accepted: September 23, 2016; Published: October 7, 2016

Copyright: © 2016 Cordeau et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by Fondation Centre de Cancérologie Charles-Bruneau: operating grant, MD; Fonds de recherche du Québec - Santé: operating grant, MD; and Fondation Centre hospitalier Universitaire Ste-Justine - Fondation des Étoiles: fellowship, MC.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CD, cluster of differentiation; CFSE, carboxyfluorescein succinimidyl ester; CSC, cancer stem cell; DNAM-1, DNAX accessory molecule 1; E:T, effector against target; FAS-L, Fas ligand; FBS, fetal bovine serum; GD2, disialoganglioside; HLA, human leukocyte antigen; IFN, interferon; IL, interleukin; KIR, killer immunoglobulin-like receptor; MICA/B, major histocompatibility complex class I-related chain A/B; NB, neuroblastoma; NK, natural killer; NKG2D, natural killer group 2D; PBMC, peripheral blood mononuclear cell; pDC, plasmacytoid dendritic cell; PE, phycoerythrin; PI, propidium iodide; PVR, poliovirus receptor; TLR, toll-like receptor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ULBP, UL16-binding protein

Introduction

Neuroblastoma (NB) is a tumor of the sympathetic nervous system and the most frequent extracranial pediatric solid tumor, occurring mostly in children before 5 years of age [1,2]. Fifty percent of NB patients >1 year of age present a high-risk metastatic disease with poor prognosis. More than one-third of these patients with high-risk NB progress under treatment or relapse despite aggressive therapeutic regimens [3–7], and most of these children will ultimately die from this disease [8–10].

Natural killer (NK) cells play important roles in tumor immunity and tumor immune surveillance [11]. The antitumor functions of NK cells are tightly regulated by the balance of activating and inhibitory signals [12]. The interaction of NK cell-activating receptors such as DNAX accessory molecule 1 (DNAM-1) and natural killer group 2D (NKG2D), with their respective ligands expressed on tumor cells, poliovirus receptor (PVR) and Nectin-2 for DNAM-1, major histocompatibility complex class I-related chain A/B (MICA/B), and UL16-binding proteins (ULBPs) for NKG2D, triggers the release of cytolytic granules by NK cells, leading to tumor cell death. NK cell lytic functions increase following cytokine stimulation or interaction with activated dendritic cells. These stimulations lead to the expression of ligands for death receptors such as Fas ligand (FAS-L) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NK cells and then to apoptosis through death-receptor pathways. In contrast, NK-cell inhibitory signals are induced by the interaction of inhibitory killer immunoglobulin-like receptors (KIR) or the heterodimer NK group 2A/CD94 expressed by NK cells with human leukocyte antigen (HLA) class I molecules expressed by target cells.

Clinically available immunotherapy for NB is based on the use of monoclonal antibodies against the surface antigen disialoganglioside (GD2) combined with granulocyte/monocyte-colony stimulating factor and interleukin (IL)-2 [7]. The efficacy of the anti-GD2 monoclonal antibodies relies not only upon complement activation, but also on antibody-mediated cellular cytotoxicity (ADCC) mediated by GM-CSF and IL-2-activated NK cells [13–19]. However, this approach has limitations. First, the use of IL-2 is associated with severe side effects. Secondly, IL-2 may not be the best cytokine to activate NK cells in patients as it increases proliferation of T regulatory cells, which could reduce NK-cell antitumor activity [20]. Additionally, NK-cell cytotoxicity is negatively regulated by inhibitory receptors recognizing self-HLA molecules on NB cells [21,22]. These hindrances can explain why one third of the patients relapse after this treatment, underlying the need for alternative approaches to increase NK-cell toxicity against NB.

Tumor relapse and metastasis of NB correlate with the presence of cancer stem cells (CSCs) within the tumor [23,24]. CSCs possess functional characteristics of stem cells such as self-renewal, quiescence, and the ability to spread into multiple metastatic tumors. Therefore, CSCs are usually resistant to chemotherapy that targets actively cycling cells and are responsible for tumor relapse [25–31]. Thus, targeting CSCs is important when designing a novel NK cell-based immunotherapy. Encouragingly, CSCs are sensitive to immunotherapy and, in particular, NK cell-based immunotherapy, due to the expression of NK cell-activating receptor ligands on CSCs [32–35]. Although NB CSC model is complex, CD133 is a surface marker associated with the stem cell-like phenotype [36–40]. In particular, we previously demonstrated that CD133⁺ SK-N-DZ NB cells are enriched in CSCs as assessed by gene expression analysis and orthotopic xenotransplantation in immunodeficient mice [23,41,42] Although not specific of NB CSCs, CD133 is thus currently the best available surface marker associated with NB stem cell-like phenotype.

Plasmacytoid dendritic cells (pDCs) are a specialized dendritic cell subset that orchestrates both innate- and adaptive-immune responses following infection challenge. In response to toll-like receptor (TLR) stimulation by viral RNA or DNA, pDCs produce high concentrations of type I interferons (IFNs), cytokines and chemokines that are strong activators of NK-cell lytic functions [43–46]. Therefore, pDCs are an attractive therapeutic tool to initiate NK cell-mediated antitumor responses.

In this study, we investigated whether TLR-activated pDCs induced NK-cell cytotoxicity against high-risk NB, including CD133⁺ and GD2⁻ cells. We explored the combination of activated pDCs and anti-GD2 antibody and determined the mechanisms of NB lysis by pDC-activated NK cells. Together, our results supported the hypothesis that patients with high-risk NB may benefit from NK-cell stimulation by activated pDCs to increase NK-cell lytic functions against NB cells.

Materials and Methods

NB Cell Lines

SJNB-7 cell line was obtained from St. Jude Hospital (Memphis, TN, USA), and SK-N-AS and SK-N-DZ cell lines were purchased from American Type Culture Collection (Manassas, VA, USA). SJNB-7 cells were derived from a primary adrenal gland tumor, while SK-N-AS and SK-N-DZ cell lines were derived from bone-marrow metastases from children with high-risk NB. All cell lines were cultured in Dulbecco's Modified Eagle Medium (Wisent Bioproducts, St-Bruno, Quebec, Canada) supplemented with 10% fetal bovine serum (FBS; Wisent Bioproducts) in a humidified atmosphere (5% CO₂) at 37°C. Passages were performed when confluence reached 80 to 90%.

Isolation of Peripheral Blood NK Cells and pDCs

NK cells and pDCs were isolated from peripheral blood samples from healthy adult volunteers. Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki after CHU Sainte Justine's Institutional Review Board approval. After peripheral blood mononuclear cell (PBMC) isolation by gradient centrifugation (Ficoll-Paque Plus, GE Healthcare, Pittsburgh, PA, USA), NK cells and pDCs were purified by negative magnetic selection (StemCell Technologies, Vancouver, BC, Canada) according to manufacturer instructions. The purity of the selected populations was assessed by flow cytometry and was always >95%.

NK Cell Stimulation

Purified NK cells were cultured in RPMI-1640 (Invitrogen, Burlington, ON, Canada) supplemented with 10% FBS at a concentration of 1 × 10⁶ cells/mL in 96-well round-bottomed plates for 20 h. NK cells were either unstimulated or stimulated by IL-15 (20 ng/mL; Miltenyi Biotec Inc., Auburn, CA, USA), IFN-α (1000 IU/mL; Merck, Kirkland, Quebec, Canada), or IL-2 (20 IU/mL; Novartis Pharmaceuticals Canada, Dorval, Quebec, Canada). For NK/pDC co-cultures, purified NK cells and pDCs were mixed at a ratio of 10:1 in the presence of CpG oligodeoxynucleotides (10 μg/mL; ODN 2216; InvivoGen, San Diego, CA, USA). For trans-well experiments, NK/pDC co-cultures were performed in 24-well plates using ThinCert inserts (Greiner Bio-One GmbH, Frickenhausen, Germany) with a 0.4-μm pore size. For type I IFN-blocking experiments in NK/pDC co-cultures, non-specific binding sites were blocked by adding 2 μg of mouse IgG2a, followed by the addition of mouse anti-human type I IFN-receptor chain 2 and anti-human IFN-α antibodies (20 μg/mL each; PBL Assay Science, Piscataway, NJ, USA).

NK Cell-Mediated Cytotoxicity Assays

NK cell-mediated cytotoxicity assays were performed by flow cytometry as described previously [47]. Briefly, NB cell lines were labeled with carboxyfluorescein succinimidyl ester (CFSE) or 3,3′-dihexyloxacarbocyanine iodide₍₁₈₎, and 10,000 labeled cells/well were plated in 96-well flat-bottomed plates and incubated overnight to allow cells to adhere. For ADCC experiments, anti-GD2 ch14.18 chimeric monoclonal antibody (mAb; 1 μg/mL; National Cancer Institute, Rockville, MD, USA) was added to NB target cells before the addition of NK cells. For blocking experiments using monoclonal antibodies against TRAIL and DNAM-1, non-specific binding sites on NK cells were blocked using mouse isotype-matched IgG before the addition of anti-human TRAIL and/or DNAM-1 monoclonal antibodies (30 μg/mL; BD Biosciences, Mississauga, ON, Canada). Unstimulated and activated NK cells were incubated in triplicate with target NB cells at different effector:target (E:T) ratios (1:1, 2.5:1, 5:1, and 10:1). After a brief centrifugation to ensure contact between effectors and targets, the plates were incubated at 37°C for 3 h. NB cells were then trypsinized and collected, counting beads and propidium iodide (PI; Invitrogen) were added to each sample, and viable NB cells were counted by flow cytometry using the BD Fortessa system (BD Biosciences, San Jose, CA, USA). SK-N-DZ cells were stained with an anti-CD133-conjugated antibody (Miltenyi Biotec, Auburn, CA, USA). Data analyses were performed using the FlowJo program (Tree Star, Ashland, OR, USA), and the percentages of specific cell lysis were calculated using the following formula:

Phenotypic Analysis of NB Cell Lines and Activated NK Cells

The phenotypes associated with SJNB-7, SK-N-AS and SK-N-DZ cell lines were assessed by flow cytometry using the following conjugated antibodies: HLA-ABC-phycoerythrin (PE) (BD Biosciences, San Jose, CA, USA), TRAIL-R1 (DR4, CD261)-allophycocyanin (APC), TRAIL-R2 (DR5, CD262)-PE (BioLegend, San Diego, CA, USA), CD95 (Fas/Apo-1)-fluorescein isothiocyanate (FITC) (BD Biosciences, San Jose, CA), CD178 (FAS-L, CD95L)-PE (Caltag, Burlington, ON, Canada), CD155-PE (PVR; BioLegend), Nectin-2-PE (CD112; BioLegend), MICA/B-PE (BioLegend), and ULBP-2-PE (R&D Systems, Minneapolis, MN, USA). Dead cells were excluded by 7-AAD) staining (BD Pharmingen, Mississauga, ON, Canada).

Following overnight stimulation, NK cells were labeled with the following antibodies: CD69-FITC, CD95 (Fas)-FITC, CD16-FITC (BD Biosciences, San Jose, CA, USA), CD56-FITC, CD336 (NKp44)-PE (BioLegend), CD253 (TRAIL)-PE, CD178 (FAS-L)-PE, CD314 (NKG2D)-PE, CD16-PE/Cy7 (BD Biosciences, San Jose, CA, USA), CD56-APC, CD335 (NKp46)-Brilliant Violet 421, CD337 (NKp30)-Alexa Fluor 647 (BioLegend), CD96-PE/V770 (Miltenyi), DNAM-1-PE (CD226, BD Biosciences, San Jose, CA, USA), and dead cells were excluded using 7-AAD staining. For perforin and granzyme intracellular staining, NK cells were first stained with the CD56-APC antibody, then fixed and permeabilized with Cytoperm/Cytofix (BD Biosciences, San Jose, CA, USA). Perforin-FITC and granzyme B-PE antibodies (BD Biosciences, San Jose, CA, USA) were then incubated according to manufacturer instructions. All acquisitions were performed on a Fortessa cytometer (BD Biosciences, San Jose, CA, USA), and data analysis was performed using the FlowJo program (Tree Star).

NK Cell-Degranulation Assay

Degranulation assays were performed as previously described [48]. Briefly, activated NK cells and target cells were mixed at a 1:1 ratio in the presence of the CD107a-PE antibody (BD Biosciences, San Jose, CA, USA) and incubated for 1 h at 37°C. GolgiStop (6 μg/mL; BD Biosciences, San Jose, CA, USA) was then added, and cells were incubated for an additional 4 h at 37°C. When required, NB target cells were first incubated with ch14.18 anti-GD2 mAb (1 μg/mL) before the co-culture with NK cells. After staining with CD56-APC antibody and addition of 7-AAD, surface expression of CD107a was assessed using a Fortessa cytometer (BD Biosciences), and data analysis was performed using the FlowJo program (Tree Star).

Statistical Analysis

One-way analysis-of-variance tests were used for multiple-group comparisons of paired data, and paired t tests were used for single-data comparisons. A p < 0.05 (*) was considered significant with a confidence interval of 99% (GraphPad Software, San Diego, CA, USA).

Results

NK Cells Stimulated with Activated pDCs Kill Both CD133⁺ and GD2⁻ NB Cells

NB are heterogeneous tumors with various phenotypes as exemplified by the diversity of GD2 and CD133 expression on NB cell lines derived from patients with high-risk NB (Fig 1A). We selected three NB cell lines (SK-N-DZ, SK-N-AS, and SJNB-7) that differed in their expression of GD2 and CD133 surface markers. We tested the ability of unstimulated or pDC-activated NK cells to kill these NB cell lines using in vitro cytotoxicity assays. In the absence of NK-cell activation, all three NB cell lines were resistant to NK cell-mediated lysis. Co-culture of NK cells with TLR-9-activated pDCs significantly increased the killing of NB cell lines, including GD2⁻ SJNB-7 cells (Fig 1B). Within the SK-N-DZ cells, CD133⁺ CSCs exhibited similar sensitivity levels as those observed in CD133⁻ cells to NK cell-mediated lysis when NK cells were stimulated by activated pDCs (Fig 1C). These results demonstrated that, following co-culture with TLR-9 stimulated pDCs, NK cells acquired the capacity to eradicate NB cells, including CSCs and GD2-negative cells.

Download:

Fig 1. NB resistance to NK cell-mediated killing is overcome by NK-cell stimulation with TLR-9-activated pDCs.

A—Phenotypic characteristics of selected NB cell lines. CD133 and GD2 expression were assessed by flow cytometry. B–In vitro cytotoxicity assays were performed against SK-N-DZ, SK-N-AS, and SJNB7 NB cell lines. NK cells and pDCs were purified from peripheral blood samples, and NK cells were stimulated with TLR9-stimulated pDCs for 18–24 h prior to the assays. Graphs represent the mean of specific lysis observed in three to five experiments, with error bars representing the standard error of the mean. C—To determine the sensitivity of CSCs to NK cell-mediated killing, SK-N-DZ cells were stained with the anti-CD133 mAb after a 3-h incubation with activated NK cells. Specific lysis of CD133⁺ and CD133⁻ SK-N-DZ cells was determined. Graphs represent the mean of specific lysis observed in three to five experiments, with error bars representing the standard error of the mean. Statistical analyses were performed using one-way analysis of variance. * p < 0.05, **p < 0.01, ***p < 0.001. CD, cluster of differentiation; CSC, cancer stem cell; GD2: disialoganglioside; NB, neuroblastoma; NK, natural killer; pDC, plasmacytoid dendritic cell; TLR, toll-like receptor.

https://doi.org/10.1371/journal.pone.0164401.g001

The Additive Effect of Activated pDCs and Anti-GD2/IL-2 on NK Cell-Mediated Killing of NB Cells in the Presence of Heterogeneous Expression of GD2

Using cytotoxic and degranulation assays, we next compared anti-GD2-targeted ADCC mediated by IL-2-stimulated NK cells with the cytotoxicity levels initiated by pDC-activated NK cells. pDC-activated NK cells and anti-GD2-targeted ADCC were equally efficient at killing GD2-expressing SK-N-DZ cells (Fig 2A). The combination of anti-GD2 mAb with pDC-mediated activation of NK cells did not increase SK-N-DZ lysis, although there was an additive effect of GD2/IL-2- and pDC-activation on granule release against SK-N-DZ cells as measured by CD107a expression on NK cells (Fig 2B). As expected, anti-GD2-mediated ADCC was inefficient at killing GD2-negative SJNB-7 cells, and these cells did not induce granule release by NK cells. Interestingly, these GD2-negative cells were killed by pDC-stimulated NK cells, thereby inducing cytotoxic granule release by pDC-activated NK cells (Fig 2A and 2B).

Download:

Fig 2. Additive effects of anti-GD2 mAb, ADCC, and pDC-activated NK-cell cytotoxicity against NB cells.

A—Cytotoxicity assays were performed against SK-N-DZ, SJNB-7, and SK-N-AS cell lines in the presence or absence of prior incubation of target cells with the anti-GD2 mAb. Effectors were either unstimulated NK cells (NS), NK cells stimulated by overnight incubation with TLR-9-activated pDCs (a-pDC), or NK cells stimulated by low doses of IL-2 alone (IL2/GD2 mAb) or in combination (IL2/GD2 mAb+a-pDC). Graphs present the specific lysis means of three independent experiments, with error bars representing the standard error of the mean. B—NK cell-degranulation assays were performed against SK-N-DZ, SJNB7, and SK-N-AS cells. Unstimulated NK (NS) and stimulated NK cells (a-pDC, IL2/GD2 mAb, or IL2/GD2 mAb+a-pDC) were incubated with target cells at a 1:1 ratio and stained with the anti-CD107a antibody. Graphs represent the means of CD107a MFIs on NK cells (gated on CD56⁺CD3⁻) in three independent experiments. Statistical analyses were performed using one-way analysis of variance. *p < 0.05, **p < 0.01, ***p < 0.001. ADCC, antibody-dependent cellular cytotoxicity; CD, cluster of differentiation; GD2: disialoganglioside; IL, interleukin; mAb, monoclonal antibody; MFI, mean fluorescence intensity; NB, neuroblastoma; NK, natural killer; pDC, plasmacytoid dendritic cell; TLR, toll-like receptor.

https://doi.org/10.1371/journal.pone.0164401.g002

Finally, we compared anti-GD2-mediated ADCC, pDC activation, and their combination in the killing of SK-N-AS cells, a NB cell line exhibiting heterogeneous expression of GD2 (Fig 2A). The efficacy of anti-GD2-mediated ADCC was much lower than that observed on GD2-positive cells, and SK-N-AS cells were sensitive to NK cells stimulated by activated pDCs. Interestingly, we observed increased killing of SK-N-AS cells by the combination of anti-GD2-mediated ADCC and pDC-mediated NK-cell activation (Fig 2A). This additive effect of ADCC and pDC-mediated NK-cell activation was associated with an increased release of cytotoxic granules (Fig 2B). Therefore, our results demonstrated that activated pDCs and anti-GD2-targeted ADCC exert an additive effect for the killing of a cell line with heterogeneous expression of GD2, leading to NB cell death comparable to that observed in a GD2-positive cell line.

Activated pDCs Induce CD69 and TRAIL Expression, as well as IFN-γ Production in NK Cells

To determine the mechanisms responsible for NK cell-mediated lysis of NB tumors, we assessed the phenotype of NK cells stimulated by either TLR-9-activated pDCs, IFN-α or IL-15. Here, we used IFN-α concentrations (1000 IU/mL) expected to be produced by activated pDCs (4 × 10⁴ cells) in the corresponding experiments [49]. We observed that the upregulation of the CD69-activation marker was significantly enhanced following NK-cell stimulation with TLR-9-activated pDCs as compared to that observed following IFN-α or IL-15 stimulation (Fig 3A). Interestingly, this upregulation of CD69 expression was observed in all CD56^dim, but not in CD56^bright NK cells, whereas CD69 expression was upregulated in only a fraction of CD56^dim (30–70% of cells, depending on the donors) and all CD56^brigh NK cells upon IFN-α and IL-15 stimulation (S1 Fig).

Download:

Fig 3. TLR9-stimulated pDCs induce a unique NK-cell phenotype and IFN-γ production.

A–C—Phenotype analysis of NK cells following overnight stimulation with IL-15, IFN-α, or co-culture with TLR9-stimulated pDCs. Graphs represent the means of MFIs for (A) CD69, (B) TRAIL, and (C) NKG2D immunostaining, with error bars representing the standard error of the mean from five to eight experiments on NK cells from different donors. D—IFN-γ production was measured by ELISA in the supernatant of NK-cell cultures following overnight stimulation. The means of four to six independent experiments are represented, with error bars representing the standard error of the mean. Statistical analyses were performed using one-way analysis of variance. *p < 0.05, **p < 0.01, ***p < 0.001. CD, cluster of differentiation; ELISA, enzyme-linked immunosorbent assay; IFN, interferon; IL, interleukin; MFI, mean fluorescence intensity; NK, natural killer; NKG2D, natural killer group 2D; pDC, plasmacytoid dendritic cell; TLR, toll-like receptor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.

https://doi.org/10.1371/journal.pone.0164401.g003

TLR-9-activated pDCs induced a significantly higher expression of TRAIL on NK cells as compared with that observed following stimulation with IFN-α or IL-15 (Fig 3B). FAS-L was not expressed on pDC-activated NK cells (S2 Fig), and natural cytotoxicity receptors (NKp44, NKp46, or NKp30), NKGD2, granzyme B and perforin were not upregulated (Fig 3C and S2 Fig).

Finally, we observed increased production of IFN-γ by NK cells stimulated by TLR-9-activated pDCs, while IFN-α stimulation did not induce IFN-γ secretion by NK cells (Fig 3D). Collectively, these results indicated that the co-culture of NK cells with TLR-9-activated pDCs induced a unique activated phenotype that cannot be reproduced by IFN-α or IL-15 stimulation alone and is characterized by increased secretion of IFN-γ, high levels of CD69 expression on CD56^dim cells, and high levels of surface expression of TRAIL on both CD56^bright and CD56^dim cells.

NK-Cell Activation by TLR-9-Activated pDCs Is Independent of Cell Contact

We next explored whether soluble factors secreted by activated pDCs or cellular contact between activated pDCs and NK cells was required for NK-cell activation. Levels of NB cell lysis were similar when NK cells and pDCs were cultured in contact or separately in trans-well experiments (Fig 4A). This result indicated that soluble factors secreted by TLR-9-activated pDCs are responsible for NK cell-mediated cytotoxicity against NB.

Download:

Fig 4. NK-cell activation is independent of contact with pDCs, but depends upon type I IFN production by activated pDCs.

A—Analysis of NK-cell cytotoxicity following NK-cell activation with TLR9-stimulated pDCs in contact or in trans-wells. Graphs are representative of three independent experiments. B—Blocking of type I IFN signaling was performed using specific blocking mAbs against IFN-α and type I IFN receptor in NK/pDC co-cultures, followed by cytotoxicity assays performed against SK-N-DZ cells. The graph represents the means of three independent experiments, with error bars representing the standard error of the mean. C—Analysis of NK-cell cytotoxicity following NK-cell activation with TLR9-stimulated pDCs (a-pDC) or IFN-α (1000 IU/mL). The IFN-α concentration was comparable to that estimated under both conditions. Specific lysis of SK-N-DZ, SK-N-AS, and SJNB-7 cells are presented for an E:T ratio of 5:1. Statistical analyses were performed using one-way analysis of variance. *p < 0.05, **p < 0.01, ***p < 0.001. E:T, effector against target; IFN, interferon; IL, interleukin; mAb, monoclonal antibody; NK, natural killer; pDC, plasmacytoid dendritic cell; TLR, toll-like receptor.

https://doi.org/10.1371/journal.pone.0164401.g004

NK-Cell Lytic Activity against NB Depends upon IFN-α Production by TLR-9-Activated pDCs, but Is Not Reproduced by IFN-α Stimulation Alone

We then determined the role of type I IFNs in NK-cell stimulation by TLR-9-activated pDCs. We blocked type I IFN signaling using a combination of blocking antibodies against IFN-α and type I IFN receptors. Type I IFN blockade completely abrogated NB cell lysis by pDC-activated NK cells (Fig 4B). To investigate whether NB killing by NK cells was entirely due to IFN-α production by pDCs, we stimulated NK cells with the amount of IFN-α expected to be produced by the 4 × 10⁴ pDCs used in the control experiments. Under these conditions, we observed that NB cell lysis was lower when NK cells were directly activated by IFN-α (Fig 4C). These results indicated that NK-cell lytic activity against NB depends upon type I IFN produced by TLR-9-activated pDCs, but is not reproduced by IFN-α stimulation alone.

The TRAIL and DNAM-1 Pathways Are Involved in NB Killing by pDC-Activated NK Cells

We investigated the role of NK cell-activating receptors, DNAM-1 and NKG2D, as well as death receptor-mediated apoptosis in NK cell-mediated lysis of NB cells using blocking experiments. We observed that all three NB cell lines expressed high levels of DNAM-1 ligands (PVR and Nectin-2) (Fig 5A–5C). Accordingly, blocking the interaction between DNAM-1 and its ligands abrogated NK cell-mediated killing of SK-N-AS and SJNB7 cells (Fig 5A and 5B) and significantly decreased SK-N-DZ cell lysis (Fig 5C).

Download:

Fig 5. The TRAIL and DNAM-1 pathways are involved in NB killing by pDC-activated NK cells.

Cytotoxicity assays against (A) SK-N-AS, (B) SJNB-7, and (C) SK-N-DZ cells were performed in the presence of DNAM-1-, TRAIL-, or NKG2D-blocking antibodies alone or in combination. Bar histograms represent the mean of three independent experiments, with error bars representing the standard error of the mean. The expression of DNAM-1 ligands (PVR and Nectin-2), TRAIL receptors (TRAIL-R1/R2), and NKG2D ligands (MICA/B and ULBP2) was investigated by flow cytometry, and representative histograms are presented for (A) SK-N-AS, (B) SJNB-7, and (C) SK-N-DZ cells. Statistical analyses were performed using one-way analysis of variance. *p < 0.05, **p < 0.01, ***p < 0.001. DNAM-1, DNAX accessory molecule 1; MICA/B, major histocompatibility complex class I-related chain A/B; NB: neuroblastoma; NK, natural killer; NKG2D, natural killer group 2D; pDC, plasmacytoid dendritic cell; PVR, poliovirus receptor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ULBP: UL16-binding protein.

https://doi.org/10.1371/journal.pone.0164401.g005

All three cell lines expressed high levels of both TRAIL receptors, TRAIl-R1 and TRAIL-R2 (Fig 5). We observed that blocking TRAIL interaction with TRAIL-R1 and TRAIL-R2 abrogated NK cell-mediated killing of SK-N-AS and SJNB7 cells and significantly decreased SK-N-DZ cell lysis (Fig 5A–5C). Additionally, NKG2D ligands (MICA/B and ULBP2) were expressed at low levels on SK-N-DZ and SJNB7 cells and were almost absent on SK-N-AS cells. Although NKG2D blockade alone did not decrease SK-N-DZ killing, the complete inhibition of cell lysis required blockage of TRAIL, DNAM-1, and NKG2D. Therefore, our findings suggested that multiple lytic pathways are engaged by pDC-activated NK cells to kill NB tumors, and that the relative role of each pathway depends upon the expression of NK-receptor ligands on target cells.

Discussion

Our study revealed that TLR-9-activated pDCs induced NK cell-mediated killing of NB cells. We demonstrated that both CD133⁺ CSCs and GD2-negative NB cells are sensitive to pDC-activated NK cell-mediated lysis. We also revealed an additive effect of NK-cell stimulation with activated pDCs and anti-GD2 ADCC for the killing of NB tumors expressing low levels of GD2. NK-cell lytic activity against NB was independent of cell contact, depended upon type I IFN produced by TLR-9-activated pDCs, but was not reproduced by IFN-α stimulation alone. Finally, our results indicated that both cytolytic granule release via NK cell-activating receptors and TRAIL-mediated apoptosis are involved in NB killing by pDC-activated NK cells.

NB may still relapse after multimodal therapy, including aggressive chemotherapy, hematopoietic stem cell transplantation, and anti-GD2 immunotherapy. CSCs are responsible for the long-term maintenance of tumor growth and metastasis due to their self-renewal properties and resistance to chemotherapy [23–31]. Given that immunotherapy is effective on low-cycling cells, CSCs from several cancer types are sensitive to immunotherapy and, in particular to NK cell-based therapy. The sensitivity of CSCs to NK cell-mediated killing is correlated to the expression of stress-induced ligands on CSCs that are recognized by the NKG2D-activator receptor expressed by NK cells [32–35]. Although the concept of CSC has been a matter of debate for NB, CD133 appears to be the best available surface marker associated CSC-like phenotype in NB, CD133⁺ NB cells being enriched in cells with a CSC-like phenotype [36–40]. Here, we showed that CD133⁺ NB cells are efficiently killed by pDC-activated NK cells. Our results are in line with data in other cancers underscoring the role of the activating receptor NKG2D in CSC killing [33,34]. Indeed the killing of the SK-N-DZ cell line (70% CD133⁺) by activated NK cells depended upon NKG2D, while the role of NKG2D was less important to the killing of the CD133⁻ NB cell lines, SK-N-AS and SJNB7.

Our results indicated that the combination of anti-GD2 immunotherapy and NK-cell stimulation with activated pDCs has the potential to eradicate NB tumors exhibiting heterogeneous expression of GD2 and to decrease the potential risk of tumor escape by GD2 downregulation. Indeed, GD2⁻ NB cells were efficiently killed by pDC-activated NK cells, and we observed an additive cytotoxic effect associated with pDC-mediated NK-cell activation and anti-GD2 ADCC against a NB cell line exhibiting heterogeneous expression of GD2. These results suggest that NK cell stimulation with activated pDCs could improve the survival rates of patients with high-risk NB treated with anti-GD2 immunotherapy.

Our results showed that efficient killing of NB cells by activated NK cells was dependent upon both DNAM-1-dependent release of cytotoxic granules and TRAIL-mediated apoptosis. These results confirmed the important role of DNAM-1 in NB killing by NK cells, exemplified by the prognostic value of DNAM-1-ligand expression on NB tumors [50,51]. These findings are in agreement with those reported by Sheard et al [44], showing that membrane-bound TRAIL plays an important role in NK cell-mediated cytotoxicity against NB cells and complements the release of cytotoxic granules. While DNAM-1 is constitutively expressed on NK cells, the expression of TRAIL is induced by NK-cell stimulation [52,53]. Importantly, high levels of TRAIL are expressed on NK cells upon stimulation by TLR-activated pDCs. This feature is unique to pDC-mediated NK-cell activation and could not be reproduced by IFN-α or IL-15 stimulation alone. This characteristic allows for the engagement of both the TRAIL-induced apoptosis pathway and DNAM-1-mediated release of cytotoxic granules by activated NK cells against NB cells.

The phenotype of NK cells activated by pDCs is characterized by two other features. First, the expression of the activation marker CD69 by CD56^dim cells signals activation of this cytolytic subset [54]. Secondly, pDC-activated NK cells secrete high levels of IFN-γ that synergize with TRAIL/death-receptor pathways. Indeed, IFN-γ promotes TRAIL-mediated cleavage of caspase-8 in NB cell lines [55,56]. Furthermore, IFN-γ can serve as a link to adaptive immunity, given that 5 days of systemic IFN-γ therapy increased T cell trafficking into tumor-biopsy specimens from patients with high-risk NB [57].

Additionally, we showed that the activation of NK cells by pDCs was dependent upon soluble factors secreted by pDCs. From a therapeutic viewpoint, it is, therefore, important to determine whether the effect of activated pDCs on NK cells can be reproduced by a single cytokine, as its administration would be simpler and more affordable than adoptive cell therapy. Because pDCs are specialized cells that produce large amounts of type I IFN in response to stimulation, the best candidate among pDC-secreted cytokines is IFN-α [58]. Accordingly, we found that type I IFN blockade completely abrogated NK-cell activation and cytotoxicity against NB, indicating that type I IFNs are required for pDC-induced NK-cell activation. However, NK-cell activation and cytotoxicity against NB were not reproduced by IFN-α stimulation alone, even at a dosage corresponding to that secreted by the number of pDCs used in these experiments. Therefore, we hypothesized that pDC-induced NK-cell stimulation is due to a combination of type I IFNs or that several other pro-inflammatory cytokines are involved. The dependency on type I IFNs may also be explained by the blockade of the IFN-α autocrine positive feedback loop needed for pDC activation [59]. Thus, it is unlikely that the administration of a single cytokine could reproduce the effect of activated pDCs on NK cell-mediated NB killing. Experiments are currently underway to test this hypothesis.

Our results contrast with those published by Perez-Martinez et al. showing that blood dendritic cells, including pDCs, suppressed NK cell functions and increased the risk of leukemia relapse after hematopoietic stem cell transplantation [60]. This discrepancy could be explained by several experimental differences between our study and that of Perez-Martinez et al. Indeed, we used the physiological NK:pDC ratio of 10:1 in our experiments, while a ratio of 2:1 was used in Perez-Martinez’ study. Moreover, we used negative selections for both pDC and NK cell purification to avoid alteration of their properties. Since our results are in good agreement with the pDC-induced NK cell activation previously described [43], we are confident that NK-cell stimulation by activated pDCs constitutes a unique therapeutic strategy to fight NB cells.

pDC activation can be induced in vivo by the administration of clinical-grade TLR-ligands [61]. However, the efficacy of this approach depends upon the number and function of pDCs in patients. We showed that, following cord-blood or allogeneic bone-marrow transplantation, pDC numbers or functions are altered for several months [49]. Whether aggressive chemotherapy, followed by autologous hematopoietic stem cell transplantation, affects pDC function and numbers in patients with high-risk NB remains to be determined. Alternatively, activated pDCs may be adoptively transferred to induce NK-cell responses. We recently developed a unique method of human pDC expansion from CD34⁺ hematopoietic stem cell progenitors [46,49]. These in vitro differentiated pDCs are as efficient as peripheral blood pDCs at inducing NK-cell antitumor activity in vitro. We further demonstrated that adoptive transfers of in vitro differentiated and activated pDCs control the development of acute lymphoblastic leukemia in humanized mice, proving the feasibility of this therapeutic approach [46]. Experiments are underway to determine whether similar therapeutic efficacy can be obtained against NB.

Our novel approach of NK-cell stimulation by activated pDCs led to the efficient killing of both CSCs and GD2⁻ NB cells and increased the efficacy of anti-GD2-mediated ADCC for NB tumors exhibiting heterogeneous expression of GD2. These results pave the way for novel immunotherapeutic strategies combining anti-GD2 mAb with pDC-mediated activation of NK cells in patients with high-risk NB to reduce the risk of relapse.

Supporting Information

S1 Fig. Flow cytometry analysis of NK cell phenotype following overnight stimulation.

Representative dot plot analysis of immunostaining with anti-CD56, anti-CD69, anti-TRAIL antibodies (gated on CD3^- cells).

https://doi.org/10.1371/journal.pone.0164401.s001

(EPS)

S2 Fig. NK cell phenotype was analyzed by flow cytometry following overnight stimulation with IL-15, IFN-α or activated pDCs.

Box plots represent the distribution of the median fluorescence intensity (MFI) of the indicated markers (NKp30, NKp46, NKp44, Fas-L, Perforin and Granzyme B). Statistical analyses were performed using one-way analysis of variance. * p < 0.05, **p < 0.01, ***p < 0.001.

https://doi.org/10.1371/journal.pone.0164401.s002

(EPS)

Acknowledgments

This work was supported by the Canadian Institutes of Health Research, The Foundation Centre de Cancérologie Charles-Bruneau, the Fonds de recherche du Québec en Santé, the Fondation CHU Sainte-Justine—Fondation des Étoiles. The authors thank Dr. Pierre Teira for critical reading of this manuscript and helpful comments and Lubomir Alexandrov for his help with statistical analyses. We would like to thank Editage (www.editage.com) for English language editing.

Author Contributions

Conceptualization: SH MD.
Formal analysis: MC SH.
Funding acquisition: MD SH.
Investigation: MC AB PC ML SH.
Methodology: MC ML SH.
Project administration: SH MD.
Resources: PC.
Supervision: SH MD.
Validation: SH.
Visualization: SH.
Writing – original draft: MC SH MD.
Writing – review & editing: HS.

References

1. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466–1477. pmid:8336186
- View Article
- PubMed/NCBI
- Google Scholar
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106–2120. pmid:17586306
- View Article
- PubMed/NCBI
- Google Scholar
3. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362: 2202–2211. pmid:20558371
- View Article
- PubMed/NCBI
- Google Scholar
4. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, et al. (1998) Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16: 953–965. pmid:9508178
- View Article
- PubMed/NCBI
- Google Scholar
5. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203–216. pmid:12612655
- View Article
- PubMed/NCBI
- Google Scholar
6. Wagner LM, Danks MK (2009) New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 107: 46–57. pmid:19277986
- View Article
- PubMed/NCBI
- Google Scholar
7. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, et al. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363: 1324–1334. pmid:20879881
- View Article
- PubMed/NCBI
- Google Scholar
8. Institute NC (2015) Neuroblastoma treatment. For Health Professionals (PDQ). Bethesda, MD: National Cancer Institute.
9. Schrey D, Vaidya SJ, Levine D, Pearson AD, Moreno L (2015) Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma. J Pediatr Hematol Oncol 37: e150–153. pmid:26201036
- View Article
- PubMed/NCBI
- Google Scholar
10. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, et al. (2015) Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 33: 3008–3017. pmid:26304901
- View Article
- PubMed/NCBI
- Google Scholar
11. Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH (2016) Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol 38: 52–58. pmid:26686774
- View Article
- PubMed/NCBI
- Google Scholar
12. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31: 227–258. pmid:23516982
- View Article
- PubMed/NCBI
- Google Scholar
13. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, et al. (1991) Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51: 144–149. pmid:1988079
- View Article
- PubMed/NCBI
- Google Scholar
14. Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, et al. (2005) Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42: 1311–1319. pmid:15950727
- View Article
- PubMed/NCBI
- Google Scholar
15. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, et al. (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91: 1706–1715. pmid:9473237
- View Article
- PubMed/NCBI
- Google Scholar
16. Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, et al. (2004) Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10: 4839–4847. pmid:15269160
- View Article
- PubMed/NCBI
- Google Scholar
17. Alvarado CS, Findley HW, Chan WC, Hnath RS, Abdel-Mageed A, et al. (1989) Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines. Cancer 63: 83–89. pmid:2783377
- View Article
- PubMed/NCBI
- Google Scholar
18. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, et al. (2010) Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16: 3901–3909. pmid:20542985
- View Article
- PubMed/NCBI
- Google Scholar
19. Castriconi R, Dondero A, Cilli M, Ognio E, Pezzolo A, et al. (2007) Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 56: 1733–1742. pmid:17426969
- View Article
- PubMed/NCBI
- Google Scholar
20. Bayer AL, Chirinos J, Cabello C, Yang J, Matsutani T, et al. (2011) Expansion of a restricted residual host T reg-cell repertoire is dependent on IL-2 following experimental autologous hematopoietic stem transplantation. Eur J Immunol 41: 3467–3478. pmid:21928285
- View Article
- PubMed/NCBI
- Google Scholar
21. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, et al. (2010) Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70: 9554–9561. pmid:20935224
- View Article
- PubMed/NCBI
- Google Scholar
22. Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, et al. (2016) KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. J Clin Oncol. pmid:27069083
- View Article
- PubMed/NCBI
- Google Scholar
23. Sartelet H, Imbriglio T, Nyalendo C, Haddad E, Annabi B, et al. (2012) CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology 60: 1144–1155. pmid:22394107
- View Article
- PubMed/NCBI
- Google Scholar
24. Tong QS, Zheng LD, Tang ST, Ruan QL, Liu Y, et al. (2008) Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr 4: 58–62. pmid:18402255
- View Article
- PubMed/NCBI
- Google Scholar
25. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105–111. pmid:11689955
- View Article
- PubMed/NCBI
- Google Scholar
26. Tan BT, Park CY, Ailles LE, Weissman IL (2006) The cancer stem cell hypothesis: a work in progress. Lab Invest 86: 1203–1207. pmid:17075578
- View Article
- PubMed/NCBI
- Google Scholar
27. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101: 14228–14233. pmid:15381773
- View Article
- PubMed/NCBI
- Google Scholar
28. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, et al. (2009) Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 4: e4235. pmid:19156211
- View Article
- PubMed/NCBI
- Google Scholar
29. Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, et al. (2009) In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 11: 426–435. pmid:19412427
- View Article
- PubMed/NCBI
- Google Scholar
30. Khalil MA, Hrabeta J, Cipro S, Stiborova M, Vicha A, et al. (2012) Neuroblastoma stem cells—mechanisms of chemoresistance and histone deacetylase inhibitors. Neoplasma 59: 737–746. pmid:22862175
- View Article
- PubMed/NCBI
- Google Scholar
31. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67. pmid:17140455
- View Article
- PubMed/NCBI
- Google Scholar
32. Castriconi R, Dondero A, Negri F, Bellora F, Nozza P, et al. (2007) Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur J Immunol 37: 3190–3196. pmid:17918205
- View Article
- PubMed/NCBI
- Google Scholar
33. Rong XX, Wei F, Lin XL, Qin YJ, Chen L, et al. (2016) Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition. Oncoimmunology 5: e1086060. pmid:27141341
- View Article
- PubMed/NCBI
- Google Scholar
34. Wei F, Rong XX, Xie RY, Jia LT, Wang HY, et al. (2015) Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition. Oncotarget 6: 35023–35039. pmid:26418951
- View Article
- PubMed/NCBI
- Google Scholar
35. Grossenbacher SK, Canter RJ, Murphy WJ (2016) Natural killer cell immunotherapy to target stem-like tumor cells. J Immunother Cancer 4: 19. pmid:27096096
- View Article
- PubMed/NCBI
- Google Scholar
36. Coulon A, Flahaut M, Muhlethaler-Mottet A, Meier R, Liberman J, et al. (2011) Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model. Neoplasia 13: 991–1004. pmid:22028624
- View Article
- PubMed/NCBI
- Google Scholar
37. Xing LL, Sha YL, Wu YM, Hu JM, Zhang M, et al. (2015) Preliminary analysis of stem cell-like cells in human neuroblastoma. World J Pediatr 11: 54–60. pmid:25431041
- View Article
- PubMed/NCBI
- Google Scholar
38. Ross RA, Walton JD, Han D, Guo HF, Cheung NK (2015) A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. Stem Cell Res 15: 419–426. pmid:26342562
- View Article
- PubMed/NCBI
- Google Scholar
39. Kamijo T (2012) Role of stemness-related molecules in neuroblastoma. Pediatr Res 71: 511–515. pmid:22430387
- View Article
- PubMed/NCBI
- Google Scholar
40. Garner EF, Beierle EA (2015) Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma. Cancers (Basel) 8. pmid:26729169
- View Article
- PubMed/NCBI
- Google Scholar
41. Cournoyer S, Nyalendo C, Addioui A, Belounis A, Beaunoyer M, et al. (2012) Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma. Genes Chromosomes Cancer 51: 792–804. pmid:22514116
- View Article
- PubMed/NCBI
- Google Scholar
42. Sartelet H, Durrieu L, Fontaine F, Nyalendo C, Haddad E (2012) Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice. In Vivo 26: 19–29. pmid:22210712
- View Article
- PubMed/NCBI
- Google Scholar
43. Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, et al. (2005) The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 174: 727–734. pmid:15634892
- View Article
- PubMed/NCBI
- Google Scholar
44. Lande R, Gilliet M (2010) Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 1183: 89–103. pmid:20146710
- View Article
- PubMed/NCBI
- Google Scholar
45. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, et al. (2007) Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 178: 1534–1541. pmid:17237402
- View Article
- PubMed/NCBI
- Google Scholar
46. Lelaidier M, Diaz-Rodriguez Y, Cordeau M, Cordeiro P, Haddad E, et al. (2015) TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells. Oncotarget 6: 29440–29455. pmid:26320191
- View Article
- PubMed/NCBI
- Google Scholar
47. Terzic T, Cordeau M, Herblot S, Teira P, Cournoyer S, et al. (2014) Expression of Disialoganglioside GD2 in neuroblastic tumors: a prognostic value for patients undergoing anti-GD2 immunotherapy. In prepartion.
- View Article
- Google Scholar
48. Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294: 15–22. pmid:15604012
- View Article
- PubMed/NCBI
- Google Scholar
49. Charrier E, Cordeiro P, Brito RM, Harnois M, Mezziani S, et al. (2014) Impaired Interferon-Alpha Production by Plasmacytoid Dendritic Cells after Cord Blood Transplantation in Children: Implication for Post-transplantation Toll-Like Receptor Ligand-Based Immunotherapy. Biol Blood Marrow Transplant. pmid:25128615
- View Article
- PubMed/NCBI
- Google Scholar
50. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, et al. (2004) Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 64: 9180–9184. pmid:15604290
- View Article
- PubMed/NCBI
- Google Scholar
51. Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, et al. (2014) Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol 5: 56. pmid:24575100
- View Article
- PubMed/NCBI
- Google Scholar
52. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, et al. (1998) Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188: 2375–2380. pmid:9858524
- View Article
- PubMed/NCBI
- Google Scholar
53. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, et al. (2001) Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 31: 3138–3146. pmid:11745330
- View Article
- PubMed/NCBI
- Google Scholar
54. Pisegna S, Zingoni A, Pirozzi G, Cinque B, Cifone MG, et al. (2002) Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells. J Immunol 169: 68–74. pmid:12077230
- View Article
- PubMed/NCBI
- Google Scholar
55. Johnsen JI, Pettersen I, Ponthan F, Sveinbjornsson B, Flaegstad T, et al. (2004) Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Int J Oncol 25: 1849–1857. pmid:15547726
- View Article
- PubMed/NCBI
- Google Scholar
56. Sheard MA, Asgharzadeh S, Liu Y, Lin TY, Wu HW, et al. (2013) Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother 36: 319–329. pmid:23719242
- View Article
- PubMed/NCBI
- Google Scholar
57. Reid GS, Shan X, Coughlin CM, Lassoued W, Pawel BR, et al. (2009) Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo. Clin Cancer Res 15: 6602–6608. pmid:19825945
- View Article
- PubMed/NCBI
- Google Scholar
58. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219–1226. pmid:15549123
- View Article
- PubMed/NCBI
- Google Scholar
59. Tailor P, Tamura T, Kong HJ, Kubota T, Kubota M, et al. (2007) The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity 27: 228–239. pmid:17702615
- View Article
- PubMed/NCBI
- Google Scholar
60. Perez-Martinez A, Iyengar R, Gan K, Chotsampancharoen T, Rooney B, et al. (2011) Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant 17: 598–607. pmid:20977942
- View Article
- PubMed/NCBI
- Google Scholar
61. Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, et al. (2014) Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 3: e29179. pmid:25083332
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466–1477. pmid:8336186
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106–2120. pmid:17586306
View Article
PubMed/NCBI
Google Scholar

[6] View Article

[7] PubMed/NCBI

[8] Google Scholar

[ref3] 3. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362: 2202–2211. pmid:20558371
View Article
PubMed/NCBI
Google Scholar

[10] View Article

[11] PubMed/NCBI

[12] Google Scholar

[ref4] 4. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, et al. (1998) Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16: 953–965. pmid:9508178
View Article
PubMed/NCBI
Google Scholar

[14] View Article

[15] PubMed/NCBI

[16] Google Scholar

[ref5] 5. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203–216. pmid:12612655
View Article
PubMed/NCBI
Google Scholar

[18] View Article

[19] PubMed/NCBI

[20] Google Scholar

[ref6] 6. Wagner LM, Danks MK (2009) New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 107: 46–57. pmid:19277986
View Article
PubMed/NCBI
Google Scholar

[22] View Article

[23] PubMed/NCBI

[24] Google Scholar

[ref7] 7. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, et al. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363: 1324–1334. pmid:20879881
View Article
PubMed/NCBI
Google Scholar

[26] View Article

[27] PubMed/NCBI

[28] Google Scholar

[ref8] 8. Institute NC (2015) Neuroblastoma treatment. For Health Professionals (PDQ). Bethesda, MD: National Cancer Institute.

[ref9] 9. Schrey D, Vaidya SJ, Levine D, Pearson AD, Moreno L (2015) Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma. J Pediatr Hematol Oncol 37: e150–153. pmid:26201036
View Article
PubMed/NCBI
Google Scholar

[31] View Article

[32] PubMed/NCBI

[33] Google Scholar

[ref10] 10. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, et al. (2015) Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 33: 3008–3017. pmid:26304901
View Article
PubMed/NCBI
Google Scholar

[35] View Article

[36] PubMed/NCBI

[37] Google Scholar

[ref11] 11. Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH (2016) Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol 38: 52–58. pmid:26686774
View Article
PubMed/NCBI
Google Scholar

[39] View Article

[40] PubMed/NCBI

[41] Google Scholar

[ref12] 12. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31: 227–258. pmid:23516982
View Article
PubMed/NCBI
Google Scholar

[43] View Article

[44] PubMed/NCBI

[45] Google Scholar

[ref13] 13. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, et al. (1991) Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51: 144–149. pmid:1988079
View Article
PubMed/NCBI
Google Scholar

[47] View Article

[48] PubMed/NCBI

[49] Google Scholar

[ref14] 14. Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, et al. (2005) Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42: 1311–1319. pmid:15950727
View Article
PubMed/NCBI
Google Scholar

[51] View Article

[52] PubMed/NCBI

[53] Google Scholar

[ref15] 15. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, et al. (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91: 1706–1715. pmid:9473237
View Article
PubMed/NCBI
Google Scholar

[55] View Article

[56] PubMed/NCBI

[57] Google Scholar

[ref16] 16. Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, et al. (2004) Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10: 4839–4847. pmid:15269160
View Article
PubMed/NCBI
Google Scholar

[59] View Article

[60] PubMed/NCBI

[61] Google Scholar

[ref17] 17. Alvarado CS, Findley HW, Chan WC, Hnath RS, Abdel-Mageed A, et al. (1989) Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines. Cancer 63: 83–89. pmid:2783377
View Article
PubMed/NCBI
Google Scholar

[63] View Article

[64] PubMed/NCBI

[65] Google Scholar

[ref18] 18. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, et al. (2010) Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16: 3901–3909. pmid:20542985
View Article
PubMed/NCBI
Google Scholar

[67] View Article

[68] PubMed/NCBI

[69] Google Scholar

[ref19] 19. Castriconi R, Dondero A, Cilli M, Ognio E, Pezzolo A, et al. (2007) Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 56: 1733–1742. pmid:17426969
View Article
PubMed/NCBI
Google Scholar

[71] View Article

[72] PubMed/NCBI

[73] Google Scholar

[ref20] 20. Bayer AL, Chirinos J, Cabello C, Yang J, Matsutani T, et al. (2011) Expansion of a restricted residual host T reg-cell repertoire is dependent on IL-2 following experimental autologous hematopoietic stem transplantation. Eur J Immunol 41: 3467–3478. pmid:21928285
View Article
PubMed/NCBI
Google Scholar

[75] View Article

[76] PubMed/NCBI

[77] Google Scholar

[ref21] 21. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, et al. (2010) Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70: 9554–9561. pmid:20935224
View Article
PubMed/NCBI
Google Scholar

[79] View Article

[80] PubMed/NCBI

[81] Google Scholar

[ref22] 22. Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, et al. (2016) KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. J Clin Oncol. pmid:27069083
View Article
PubMed/NCBI
Google Scholar

[83] View Article

[84] PubMed/NCBI

[85] Google Scholar

[ref23] 23. Sartelet H, Imbriglio T, Nyalendo C, Haddad E, Annabi B, et al. (2012) CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology 60: 1144–1155. pmid:22394107
View Article
PubMed/NCBI
Google Scholar

[87] View Article

[88] PubMed/NCBI

[89] Google Scholar

[ref24] 24. Tong QS, Zheng LD, Tang ST, Ruan QL, Liu Y, et al. (2008) Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr 4: 58–62. pmid:18402255
View Article
PubMed/NCBI
Google Scholar

[91] View Article

[92] PubMed/NCBI

[93] Google Scholar

[ref25] 25. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105–111. pmid:11689955
View Article
PubMed/NCBI
Google Scholar

[95] View Article

[96] PubMed/NCBI

[97] Google Scholar

[ref26] 26. Tan BT, Park CY, Ailles LE, Weissman IL (2006) The cancer stem cell hypothesis: a work in progress. Lab Invest 86: 1203–1207. pmid:17075578
View Article
PubMed/NCBI
Google Scholar

[99] View Article

[100] PubMed/NCBI

[101] Google Scholar

[ref27] 27. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101: 14228–14233. pmid:15381773
View Article
PubMed/NCBI
Google Scholar

[103] View Article

[104] PubMed/NCBI

[105] Google Scholar

[ref28] 28. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, et al. (2009) Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 4: e4235. pmid:19156211
View Article
PubMed/NCBI
Google Scholar

[107] View Article

[108] PubMed/NCBI

[109] Google Scholar

[ref29] 29. Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, et al. (2009) In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 11: 426–435. pmid:19412427
View Article
PubMed/NCBI
Google Scholar

[111] View Article

[112] PubMed/NCBI

[113] Google Scholar

[ref30] 30. Khalil MA, Hrabeta J, Cipro S, Stiborova M, Vicha A, et al. (2012) Neuroblastoma stem cells—mechanisms of chemoresistance and histone deacetylase inhibitors. Neoplasma 59: 737–746. pmid:22862175
View Article
PubMed/NCBI
Google Scholar

[115] View Article

[116] PubMed/NCBI

[117] Google Scholar

[ref31] 31. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67. pmid:17140455
View Article
PubMed/NCBI
Google Scholar

[119] View Article

[120] PubMed/NCBI

[121] Google Scholar

[ref32] 32. Castriconi R, Dondero A, Negri F, Bellora F, Nozza P, et al. (2007) Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur J Immunol 37: 3190–3196. pmid:17918205
View Article
PubMed/NCBI
Google Scholar

[123] View Article

[124] PubMed/NCBI

[125] Google Scholar

[ref33] 33. Rong XX, Wei F, Lin XL, Qin YJ, Chen L, et al. (2016) Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition. Oncoimmunology 5: e1086060. pmid:27141341
View Article
PubMed/NCBI
Google Scholar

[127] View Article

[128] PubMed/NCBI

[129] Google Scholar

[ref34] 34. Wei F, Rong XX, Xie RY, Jia LT, Wang HY, et al. (2015) Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition. Oncotarget 6: 35023–35039. pmid:26418951
View Article
PubMed/NCBI
Google Scholar

[131] View Article

[132] PubMed/NCBI

[133] Google Scholar

[ref35] 35. Grossenbacher SK, Canter RJ, Murphy WJ (2016) Natural killer cell immunotherapy to target stem-like tumor cells. J Immunother Cancer 4: 19. pmid:27096096
View Article
PubMed/NCBI
Google Scholar

[135] View Article

[136] PubMed/NCBI

[137] Google Scholar

[ref36] 36. Coulon A, Flahaut M, Muhlethaler-Mottet A, Meier R, Liberman J, et al. (2011) Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model. Neoplasia 13: 991–1004. pmid:22028624
View Article
PubMed/NCBI
Google Scholar

[139] View Article

[140] PubMed/NCBI

[141] Google Scholar

[ref37] 37. Xing LL, Sha YL, Wu YM, Hu JM, Zhang M, et al. (2015) Preliminary analysis of stem cell-like cells in human neuroblastoma. World J Pediatr 11: 54–60. pmid:25431041
View Article
PubMed/NCBI
Google Scholar

[143] View Article

[144] PubMed/NCBI

[145] Google Scholar

[ref38] 38. Ross RA, Walton JD, Han D, Guo HF, Cheung NK (2015) A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. Stem Cell Res 15: 419–426. pmid:26342562
View Article
PubMed/NCBI
Google Scholar

[147] View Article

[148] PubMed/NCBI

[149] Google Scholar

[ref39] 39. Kamijo T (2012) Role of stemness-related molecules in neuroblastoma. Pediatr Res 71: 511–515. pmid:22430387
View Article
PubMed/NCBI
Google Scholar

[151] View Article

[152] PubMed/NCBI

[153] Google Scholar

[ref40] 40. Garner EF, Beierle EA (2015) Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma. Cancers (Basel) 8. pmid:26729169
View Article
PubMed/NCBI
Google Scholar

[155] View Article

[156] PubMed/NCBI

[157] Google Scholar

[ref41] 41. Cournoyer S, Nyalendo C, Addioui A, Belounis A, Beaunoyer M, et al. (2012) Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma. Genes Chromosomes Cancer 51: 792–804. pmid:22514116
View Article
PubMed/NCBI
Google Scholar

[159] View Article

[160] PubMed/NCBI

[161] Google Scholar

[ref42] 42. Sartelet H, Durrieu L, Fontaine F, Nyalendo C, Haddad E (2012) Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice. In Vivo 26: 19–29. pmid:22210712
View Article
PubMed/NCBI
Google Scholar

[163] View Article

[164] PubMed/NCBI

[165] Google Scholar

[ref43] 43. Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, et al. (2005) The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 174: 727–734. pmid:15634892
View Article
PubMed/NCBI
Google Scholar

[167] View Article

[168] PubMed/NCBI

[169] Google Scholar

[ref44] 44. Lande R, Gilliet M (2010) Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 1183: 89–103. pmid:20146710
View Article
PubMed/NCBI
Google Scholar

[171] View Article

[172] PubMed/NCBI

[173] Google Scholar

[ref45] 45. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, et al. (2007) Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 178: 1534–1541. pmid:17237402
View Article
PubMed/NCBI
Google Scholar

[175] View Article

[176] PubMed/NCBI

[177] Google Scholar

[ref46] 46. Lelaidier M, Diaz-Rodriguez Y, Cordeau M, Cordeiro P, Haddad E, et al. (2015) TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells. Oncotarget 6: 29440–29455. pmid:26320191
View Article
PubMed/NCBI
Google Scholar

[179] View Article

[180] PubMed/NCBI

[181] Google Scholar

[ref47] 47. Terzic T, Cordeau M, Herblot S, Teira P, Cournoyer S, et al. (2014) Expression of Disialoganglioside GD2 in neuroblastic tumors: a prognostic value for patients undergoing anti-GD2 immunotherapy. In prepartion.
View Article
Google Scholar

[183] View Article

[184] Google Scholar

[ref48] 48. Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294: 15–22. pmid:15604012
View Article
PubMed/NCBI
Google Scholar

[186] View Article

[187] PubMed/NCBI

[188] Google Scholar

[ref49] 49. Charrier E, Cordeiro P, Brito RM, Harnois M, Mezziani S, et al. (2014) Impaired Interferon-Alpha Production by Plasmacytoid Dendritic Cells after Cord Blood Transplantation in Children: Implication for Post-transplantation Toll-Like Receptor Ligand-Based Immunotherapy. Biol Blood Marrow Transplant. pmid:25128615
View Article
PubMed/NCBI
Google Scholar

[190] View Article

[191] PubMed/NCBI

[192] Google Scholar

[ref50] 50. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, et al. (2004) Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 64: 9180–9184. pmid:15604290
View Article
PubMed/NCBI
Google Scholar

[194] View Article

[195] PubMed/NCBI

[196] Google Scholar

[ref51] 51. Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, et al. (2014) Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol 5: 56. pmid:24575100
View Article
PubMed/NCBI
Google Scholar

[198] View Article

[199] PubMed/NCBI

[200] Google Scholar

[ref52] 52. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, et al. (1998) Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188: 2375–2380. pmid:9858524
View Article
PubMed/NCBI
Google Scholar

[202] View Article

[203] PubMed/NCBI

[204] Google Scholar

[ref53] 53. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, et al. (2001) Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 31: 3138–3146. pmid:11745330
View Article
PubMed/NCBI
Google Scholar

[206] View Article

[207] PubMed/NCBI

[208] Google Scholar

[ref54] 54. Pisegna S, Zingoni A, Pirozzi G, Cinque B, Cifone MG, et al. (2002) Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells. J Immunol 169: 68–74. pmid:12077230
View Article
PubMed/NCBI
Google Scholar

[210] View Article

[211] PubMed/NCBI

[212] Google Scholar

[ref55] 55. Johnsen JI, Pettersen I, Ponthan F, Sveinbjornsson B, Flaegstad T, et al. (2004) Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Int J Oncol 25: 1849–1857. pmid:15547726
View Article
PubMed/NCBI
Google Scholar

[214] View Article

[215] PubMed/NCBI

[216] Google Scholar

[ref56] 56. Sheard MA, Asgharzadeh S, Liu Y, Lin TY, Wu HW, et al. (2013) Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother 36: 319–329. pmid:23719242
View Article
PubMed/NCBI
Google Scholar

[218] View Article

[219] PubMed/NCBI

[220] Google Scholar

[ref57] 57. Reid GS, Shan X, Coughlin CM, Lassoued W, Pawel BR, et al. (2009) Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo. Clin Cancer Res 15: 6602–6608. pmid:19825945
View Article
PubMed/NCBI
Google Scholar

[222] View Article

[223] PubMed/NCBI

[224] Google Scholar

[ref58] 58. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219–1226. pmid:15549123
View Article
PubMed/NCBI
Google Scholar

[226] View Article

[227] PubMed/NCBI

[228] Google Scholar

[ref59] 59. Tailor P, Tamura T, Kong HJ, Kubota T, Kubota M, et al. (2007) The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity 27: 228–239. pmid:17702615
View Article
PubMed/NCBI
Google Scholar

[230] View Article

[231] PubMed/NCBI

[232] Google Scholar

[ref60] 60. Perez-Martinez A, Iyengar R, Gan K, Chotsampancharoen T, Rooney B, et al. (2011) Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant 17: 598–607. pmid:20977942
View Article
PubMed/NCBI
Google Scholar

[234] View Article

[235] PubMed/NCBI

[236] Google Scholar

[ref61] 61. Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, et al. (2014) Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 3: e29179. pmid:25083332
View Article
PubMed/NCBI
Google Scholar

[238] View Article

[239] PubMed/NCBI

[240] Google Scholar

Figures

Abstract

Introduction

Materials and Methods

NB Cell Lines

Isolation of Peripheral Blood NK Cells and pDCs

NK Cell Stimulation

NK Cell-Mediated Cytotoxicity Assays

Phenotypic Analysis of NB Cell Lines and Activated NK Cells

NK Cell-Degranulation Assay

Statistical Analysis

Results

NK Cells Stimulated with Activated pDCs Kill Both CD133+ and GD2− NB Cells

The Additive Effect of Activated pDCs and Anti-GD2/IL-2 on NK Cell-Mediated Killing of NB Cells in the Presence of Heterogeneous Expression of GD2

Activated pDCs Induce CD69 and TRAIL Expression, as well as IFN-γ Production in NK Cells

NK-Cell Activation by TLR-9-Activated pDCs Is Independent of Cell Contact

NK-Cell Lytic Activity against NB Depends upon IFN-α Production by TLR-9-Activated pDCs, but Is Not Reproduced by IFN-α Stimulation Alone

The TRAIL and DNAM-1 Pathways Are Involved in NB Killing by pDC-Activated NK Cells

Discussion

Supporting Information

S1 Fig. Flow cytometry analysis of NK cell phenotype following overnight stimulation.

S2 Fig. NK cell phenotype was analyzed by flow cytometry following overnight stimulation with IL-15, IFN-α or activated pDCs.

Acknowledgments

Author Contributions

References

NK Cells Stimulated with Activated pDCs Kill Both CD133⁺ and GD2⁻ NB Cells